New England Journal of Medicine · 2012 · 1.3K citations · 15 references
MedicineHematologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyHemostasisAnticoagulant TherapyDeep Vein ThrombosisPulmonary EmbolismThromboembolic DiseaseThrombosisVenous ThromboembolismDeep Vein Thrombosis ManagementDeep Vein Thrombosis ProphylaxisDeep Vein Thrombosis TreatmentExtended-duration AnticoagulationPharmacologic Thromboprophylaxis
BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. RESULTS: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. CONCLUSIONS: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
15
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger, John H. Alexander, John J.V. McMurray et al. · New England Journal of Medicine · 2011 · 8.9K citations · Full text
Antithrombotic Therapy for VTE Disease
Clive Kearon, Elie A. Akl, Anthony J. Comerota et al. · CHEST Journal · 2012 · 6.1K citations · Full text
A sharper Bonferroni procedure for multiple tests of significance
Yosef Hochberg · Biometrika · 1988 · 4.7K citations
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
New England Journal of Medicine · 2010 · 3.2K citations · Full text
Guidelines on the diagnosis and management of acute pulmonary embolism
Adam Torbicki, Arnaud Perrier, Stavros Konstantinides et al. · European Heart Journal · 2008 · 2.8K citations · Full text